רווח למניה בשנים עשר החודשים האחרונים: Erasca Inc (ERAS)

Erasca, Inc. (ERAS) is implementing comprehensive therapies to block RAS/MAPK pathways, preventing tumor resistance. However, high development costs and the risk of clinical trial failure create financial threats. The company's patent portfolio and the high barriers to entry in the sector serve as a defense. The 12-month net income per share snapshot captures the profitability trend, where the metric value stands at -0.95.

For Erasca, Inc. (ERAS), which possesses high scientific authority in oncology, earnings per share over the last four quarters serve as an indicator of the efficiency of clinical trial cost management. This metric is calculated by dividing the total annual net income by the total number of shares, allowing the investor to assess the real profitability of the business, stripped of market noise and volatility.